Lisa Richardson named director of CDC Division of Cancer Prevention and Control

LISA RICHARDSON was named director of the CDC Division of Cancer Prevention and Control.

Richardson served for over a decade in medical and scientific leadership roles in the division and will rejoin the center Nov. 16.

She first joined CDC in 1997 as medical officer in DCPC’s National Breast and Cervical Cancer Early Detection Program and was then selected as medical officer of the Hematologic Diseases Branch in the National Center for Infectious Diseases.

She left CDC in late 2000 to practice clinical care and serve as assistant professor at the University of Florida’s School of Medicine. Richardson then returned to CDC in 2004 as medical officer and served as lead of the Scientific Support and Clinical Translation Team in the Comprehensive Cancer Control Branch and as the division’s associate director for science. She then left DCPC in April 2013 to direct the Division of Blood Disorders in the National Center for Birth Defects and Developmental Disabilities.

Pamela Protzel Berman, who served as acting director of DCPC, will return to her full-time duties as DCPC’s deputy director.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

In The Headlines: Back to “business as usual” at FDA?

The Oncologic Drugs Advisory Committee held its first session since President Trump’s inauguration, with a two-day, back-to-back marathon meeting, signaling a return to business at FDA after significant upheaval at the agency.

May 28, 2025

Vol.51 No.20

Regulatory News

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.

May 23, 2025

Vol.51 No.20

By Jacquelyn Cobb

Clinical Trials & Tribulations

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising.

May 23, 2025

Vol.51 No.20

By Peter Nelson

Clinical Trials & Tribulations

Unlocking the future of precision medicine:
The untapped power of RNA

True innovation in healthcare requires us to look beyond the obvious. For years, DNA sequencing has been the key pillar of precision medicine, offering insights into disease predispositions, mechanisms, and diagnosis that inform treatment.

May 23, 2025

Vol.51 No.20

By Eric Lefkofsky and Norman E. "Ned" Sharpless

Clinical

A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors

The American Society of Clinical Oncology and Google Cloud have developed a tool called the ASCO Guidelines Assistant to help oncologists parse through and interpret clinical practice guidelines.

May 23, 2025

Vol.51 No.20

By Claire Marie Porter

PAMN becomes CMCA—the Cancer Marketing & Communications Association—as its size and scope expand

As the leaders of the Public Affairs & Marketing Network set out to develop a strategic plan four years ago, they had to confront one surprising challenge.

May 23, 2025

Vol.51 No.20

By Jacquelyn Cobb

Lisa Richardson named director of CDC Division of Cancer Prevention and Control

YOU MAY BE INTERESTED IN

In The Headlines: Back to “business as usual” at FDA?

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Unlocking the future of precision medicine:
The untapped power of RNA

A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors

PAMN becomes CMCA—the Cancer Marketing & Communications Association—as its size and scope expand

Renew today!

Subscriber content

Never miss an issue!

Login

Lisa Richardson named director of CDC Division of Cancer Prevention and Control

YOU MAY BE INTERESTED IN

In The Headlines: Back to “business as usual” at FDA?

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

Biden’s diagnosis is unfortunate but—statistically—not surprisingOf the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Unlocking the future of precision medicine:The untapped power of RNA

A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors

PAMN becomes CMCA—the Cancer Marketing & Communications Association—as its size and scope expand

Never miss an issue!

Login

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Unlocking the future of precision medicine:
The untapped power of RNA